Menu
1 min read · estimated
APPROVED USE
What FDA approved
Pimicotinib for adults with symptomatic tenosynovial giant cell tumor when resection could worsen functional limitation or cause severe morbidity.
SUPPORTING DATA
Evidence behind the decision
- Study
- MANEUVER: double-blind, randomized, placebo-controlled international trial.
- Key result
- Week-25 response by blinded central review was 56% (95% CI 42-68) versus 3.2% (95% CI 0.1-17).
- Safety to report
- FDA warns about hepatotoxicity, embryo-fetal toxicity and increased creatinine without impaired renal function.
- Evidence limits
- The trial compared treatment with placebo, not another active TGCT therapy. FDA's annual novel-drug table lists November 13; the approval letter and oncology notice establish November 10 as the action date.
LAMPGEN ANALYSIS
Why it matters
This nonmalignant tumor decision fits the tracker's stated scope. Functional outcomes matter alongside radiographic response.
What research teams should watch
Document surgical risk, preserve consistent baseline imaging, and standardize joint-function and patient-reported assessments.
PRIMARY RECORDS